CSIMarket Company Name, Ticker, Suppliers, else..
 
Greenwich Lifesciences Inc   (NASDAQ: GLSI)
Other Ticker:  
 
 
Price: $10.6300 $-0.02 -0.188%
Day's High: $11.1285 Week Perf: -6.26 %
Day's Low: $ 10.59 30 Day Perf: -8.12 %
Volume (M): 28 52 Wk High: $ 20.55
Volume (M$): $ 292 52 Wk Avg: $13.80
Open: $10.66 52 Wk Low: $10.20



 Market Capitalization (Millions $) 140
 Shares Outstanding (Millions) 13
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Greenwich Lifesciences Inc
Greenwich Lifesciences Inc is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapy drug candidates for the treatment of solid tumors. The company's lead product candidate, GP2, is a novel peptide immunotherapy intended to prevent breast cancer recurrence in patients who have previously undergone surgery. GP2 stimulates the immune system to recognize and destroy breast cancer cells expressing the HER2/neu protein, which is known to be present in certain breast cancer patients. Greenwich Lifesciences aims to provide an effective and safe treatment option for breast cancer patients at high risk of recurrence, ultimately improving their long-term outcomes.


   Company Address: 3992 Bluebonnet Dr. Stafford 77477 TX
   Company Phone Number: 819-3232   Stock Exchange / Ticker: NASDAQ GLSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.4%    
LGND   -1.21%    
PFE   -4.34%    
RYTM        0.13% 
SUPN        0.03% 
YMAB   -1.4%    
• View Complete Report
   



2seventy Bio Inc

2seventy Bio Inc announced top-line has dropped by -72.613 %, all along the fiscal span closing Dec 31 2024

For the financial fourth quarter of 2024 TSVT lost money of $-0.37 per share compare to $-0.89 a year ago and grew shortfall from $-0.19 per share from the prior reporting season. The revenue fell sharply by -72.613 % to $2.93 million from $10.68 million in the comparable reporting season a year ago and sequentially Revenue Tumbled by -78.38 % from $13.53 million.

Kezar Life Sciences Inc

The company declared operating shortfall in the fourth quarter of 2024

The shareholders did not anticipate any modifications at the top-line during the the earnings season of the October to December 31 2024 at the company. Yet, they observe KZRs' operating shortfall that came in at $-21.563 million, during the matching time.

Corvus Pharmaceuticals Inc

Among many businesses, the CRVS disclosed as well its fourth quarter of 2024 effort

The Major Pharmaceutical Preparations sector researchers continue to scrutinize the fourth quarter of 2024 performance. Presently those researchers follow operating shortfall of $-8.105 million, from the company, as it hasn't mentioned any top-line yet, for the respective October to December 31 2024 reporting period.

Aprea Therapeutics Inc

Observing the fourth quarter of 2024 effort, APREs' had the shortfall has been reduced exceptionally

Energetic Revenue elevation in its most recent fiscal period, by 61.344 % to $0.94 million fueled to cut losses to $-0.35 per share, from $-0.92 in comparable reporting period a year before. Major Pharmaceutical Preparations company's top-line rose at higher rate in contrast to the the revenue at almost all of the Major Pharmaceutical Preparations sector peers, in the fourth quarter of 2024 the two third companies in Major Pharmaceutical Preparations sectors had the top-line elevation of 12.00% from the comparable reporting period a year ago.

Optinose Inc

Revenue have been $22.419 million at the OPTN in October to December 31 2024 time-frame

For the October to December 31 2024 time-frame company reached zero gain of $0.00 per share compare to $-0.07 a year ago and from $0.00 per share from the prior reporting period. The revenue were up by 12.862 % to $22.42 million from $19.86 million in the same reporting period a year ago and sequentially revenue advanced by 9.698 % from $20.44 million. Optinose Inc s' has clearly outpaced its industry contemporaries on the business angle, as the Major Pharmaceutical Preparations industry show 12.00% during the matching time revenue advance so far.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com